Conference Reports for NATAP

66th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 13-17 2015 Back

No Pharmacokinetic Interaction Between HCV NS5A Inhibitor Elbasvir and Buprenorphine/Naloxone in Healthy Volunteers - C-EDGE C-Star Study: Grazoprevir/Elbasvir in IDUs on Opioid Antagonist Therapy       Reported by Jules Levin AASLD 2015 Nov 13-17 San Francisco   William L. Marshall1; Ted Marenco2; Hwa-Ping Feng1; April M. Barbour1; Jocelyn Gilmartin1; Fang Liu1; Deborah Panebianco1; Angela Mirzac2; Mike Di Spirito2; Daria Stypinski2; Ziv Machnes2; Michael Gartner2; Marian Iwamoto1; Joan R. Butterton1; Wendy W. Yeh1 1Merck & Co., Inc., Kenilworth, NJ, USA; 2Celerion, Lincoln, NE, USA   AASLD: C-EDGE CO-STAR: efficacy of grazoprevir / elbasvir Fixed Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy - (11/16/15)   AASLD: Eliminate Restrictions to Substance Users/Injection Drug Users - SVR Rates the Same in New Study as in Non-IDUs 96% - Routine HCV Testing is needed - (11/18/15)   AASLD: Merck at AASLD / HepDart 2015 - (01/14/16)